PRAMEF1

Across TCGA pan-cancer cohorts, PRAMEF1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of PRAMEF1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRAMEF1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRAMEF1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

KIRC, BRCA, and THCA are the cancer types where PRAMEF1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRAMEF1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	III,IV	+0.004	.023	6	view →
BRCA	All	All	+0.004	.023	4	view →
THCA	All	All	−0.011	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

PRAMEF1–KIRC

Open the KIRC breakdown →